SCHEMBL6512113

SCHEMBL6512113

[O]C(c1ccccc1)(C(F)(F)F)C(F)(F)F

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.55
ALDH1A1 P00352 2/20 0.55
PTPN1 P18031 2/20 0.48
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
CA5A P35218 1/20 0.46
CA9 Q16790 1/20 0.46
KCNN4 O15554 5/20 0.41
KIF11 P52732 1/20 0.40
PGK1 P00558 1/20 0.39
PGK2 P07205 1/20 0.39
MAPT P10636 2/20 0.39
S1PR4 O95977 1/20 0.39
LMNA P02545 1/20 0.39
S1PR1 P21453 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
CYP1A2 P05177 1/20 0.39
CES1 P23141 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.38
PTPN5 P54829 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8333825 0.80 PGK1 (0.48) TSHRALDH1A1PTPN1CA1CA2
SCHEMBL28114684 0.80 TSHR (0.52) TSHRALDH1A1PTPN1CA1CA2
SCHEMBL424619 0.79 TSHR (0.58) TSHRALDH1A1PTPN1CA1CA2
SCHEMBL17078011 0.74 ALDH1A1 (0.52) TSHRALDH1A1PTPN1CA1CA2
SCHEMBL17288747 0.73 TSHR (0.58) TSHRALDH1A1PTPN1CA1CA2
SCHEMBL612731 0.73 ALDH1A1 (0.58) TSHRALDH1A1PTPN1CA1CA2
SCHEMBL951559 0.73 TSHR (0.58) TSHRALDH1A1PTPN1CA1CA2
SCHEMBL11546152 0.73 TSHR (0.58) TSHRALDH1A1PTPN1CA1CA2
SCHEMBL160204 0.73 TSHR (0.58) TSHRALDH1A1PTPN1CA1CA2
SCHEMBL146900 0.73 TSHR (0.58) TSHRALDH1A1PTPN1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11779911-B2 Production of fatty olefin derivatives via olefin metathesis PROVIVI, INC. (US) 2023-10-10 US claimed
CN-115215748-A Production of aliphatic olefin derivatives by olefin metathesis 普罗维维公司 2022-10-21 CN claimed
US-20220032280-A1 PRODUCTION OF FATTY OLEFIN DERIVATIVES VIA OLEFIN METATHESIS PROVIVI, INC. (US) 2022-02-03 US claimed
EP-3019510-B1 USE OF IMMOBILIZED MOLYBDEN- UND TUNGSTEN-CONTAINING CATALYSTS IN OLEFIN CROSS METATHESIS VERBIO VER BIOENERGIE AG (DE) 2020-12-02 EP claimed
EP-3662996-A2 MOLYBDENUM AND TUNGSTEN COMPLEXES AS OLEFIN METATHESIS CATALYSTS AND REACTIONS USING THE CATALYSTS Verbio Vereinigte BioEnergie AG (DE) 2020-06-10 EP claimed
CN-110603240-A Synthesis of pheromones and related substances via olefin metathesis 普罗维维公司 2019-12-20 CN claimed
EP-2703081-B1 MOLYBDENUM AND TUNGSTEN COMPLEXES AS OLEFIN METATHESIS CATALYSTS AND REACTIONS USING THE CATALYSTS XIMO AG (CH) 2019-08-07 EP claimed
US-10343153-B2 Metathesis catalysts and reactions using the catalysts XIMO AG (CH) 2019-07-09 US claimed
EP-3377465-A2 PRODUCTION OF FATTY OLEFIN DERIVATIVES VIA OLEFIN METATHESIS Provivi, Inc. (US) 2018-09-26 EP claimed
US-10071950-B2 Use of immobilized molybdenum- and tungsten-containing catalysts in olefin cross metathesis XIMO AG (CH) 2018-09-11 US claimed
US-20160030936-A1 METATHESIS CATALYSTS AND REACTIONS USING THE CATALYSTS VERBIO SE (DE) 2016-02-04 US claimed
EP-2969204-A2 MOLYBDENUM AND TUNGSTEN COMPLEXES AS OLEFIN METATHESIS CATALYSTS AND REACTIONS USING THE CATALYSTS XiMo AG (CH) 2016-01-20 EP claimed
US-20140309466-A1 METATHESIS CATALYSTS AND REACTIONS USING THE CATALYSTS VERBIO SE (DE) 2014-10-16 US claimed
WO-2014139679-A2 METATHESIS CATALYSTS AND REACTIONS USING THE CATALYSTS XIMO AG (CH) 2014-09-18 WO claimed
EP-2703081-A1 Molybdenum and tungsten complexes as olefin metathesis catalysts and reactions using the catalysts XiMo AG (CH) 2014-03-05 EP claimed
EP-1292579-A1 SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRAZINONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE Pharmacia Corporation (US) 2003-03-19 EP claimed
WO-2001087854-A1 SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRAZINONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE PHARMACIA CORPORATION (US) 2001-11-22 WO claimed
WO-2001087851-A1 SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRIMIDINONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE PHARMACIA CORPORATION (US) 2001-11-22 WO claimed
WO-2001087842-A1 SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRIDONES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE PHARMACIA CORPORATION (US) 2001-11-22 WO claimed
WO-2001087852-A1 SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL URACILS USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE PHARMACIA CORPORATION (US) 2001-11-22 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10343153-B2 Metathesis catalysts and reactions using the catalysts MSMO1, SQLE, MOGAT2 TSHR 4219/4885ALDH1A1 994/4885PTPN1 4696/4885
US-20140309466-A1 METATHESIS CATALYSTS AND REACTIONS USING THE CATALYSTS MSMO1, PYM1, SQLE TSHR 2482/4885ALDH1A1 2361/4885PTPN1 4326/4885
US-20160030936-A1 METATHESIS CATALYSTS AND REACTIONS USING THE CATALYSTS MSMO1, SQLE, PYM1 TSHR 2403/4885ALDH1A1 1956/4885PTPN1 4333/4885
US-11779911-B2 Production of fatty olefin derivatives via olefin metathesis SREBF1, F2, SREBF2 TSHR 1977/4885ALDH1A1 1913/4885PTPN1 4802/4885
US-20220032280-A1 PRODUCTION OF FATTY OLEFIN DERIVATIVES VIA OLEFIN METATHESIS SREBF1, F2, SREBF2 TSHR 1977/4885ALDH1A1 1913/4885PTPN1 4802/4885
US-10071950-B2 Use of immobilized molybdenum- and tungsten-containing catalysts in olefin cross metathesis DUOX1, DUOX2, MSN TSHR 4162/4885ALDH1A1 1742/4885PTPN1 4721/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.